Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Probiotics  COVID-19 treatment studies for Probiotics  C19 studies: Probiotics  Probiotics   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Recovery 33% Improvement Relative Risk Recovery (b) 53% Recovery (c) 20% Recovery (d) 26% c19probiotics.com Navarro-López et al. NCT04390477 Probiotics RCT EARLY Favors probiotics Favors control
Navarro-López, 39 patient probiotics early treatment RCT: 33% improved recovery [p=0.08] https://c19p.org/navarrolopez
copied to clipboard
Oral intake of Kluyveromyces marxianus B0399 plus lactobacillus rhamnosus CECT 30579 to mitigate symptoms in COVID-19 patients: A randomized open label clinical trial
Navarro-López et al., Medicine in Microecology, doi:10.1016/j.medmic.2022.100061, NCT04390477 (history)
24 Aug 2022    Source   PDF   Share   Tweet
RCT with 24 probiotics and 15 control patients in Spain, showing lower overall symptoms and lower digestive symptoms with treatment. Kluyveromyces marxianus B0399 plus lactobacillus rhamnosus CECT 30579.
The immune effects of probiotics are strain-specific.
risk of no recovery, 32.7% lower, RR 0.67, p = 0.08, treatment 14 of 24 (58.3%), control 13 of 15 (86.7%), NNT 3.5, day 30.
risk of no recovery, 53.1% lower, RR 0.47, p = 0.10, treatment 6 of 24 (25.0%), control 8 of 15 (53.3%), NNT 3.5, digestive symptoms, day 30.
relative recovery, 20.0% better, RR 0.80, p = 0.03, treatment 24, control 15, relative symptom improvement, day 30.
relative recovery, 26.1% better, RR 0.74, p = 0.06, treatment 24, control 15, relative improvement for digestive symptoms, day 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Navarro-López et al., 24 Aug 2022, Randomized Controlled Trial, Spain, peer-reviewed, 13 authors, study period December 2020 - February 2021, trial NCT04390477 (history).
Contact: vnavarro@ucam.edu (corresponding author), pedro.sanchez@bioithas.com, juan.aguera@bioithas.com, eva.nunez@bioithas.com, beatriz.ruzafa@bioithas.com, laura.navarro@bioithas.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperProbioticsAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit